Quarterly report · Q1
4572.TEDINET S100QP76
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥227m | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥555m | 2022-01-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥506m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥1m | 2022-01-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥513m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5m | 2022-01-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥514m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥11m | 2022-01-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥4.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥547m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.5bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-32.78 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.12 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 88.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥570m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥64m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥108m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥109m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 304
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)西 方 実 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)安 場 達 哉 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 554650000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 226967000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 1386748000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 4576000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -513368000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -1278820000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | -15104000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -519210000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -1349539000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 31390000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | -518278000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -1331861000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 4540757000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 4397841000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 3641844000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 5355256000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 4945261000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 4266453000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | -1.12 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -32.78 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -99.10 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.846 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.888 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.850 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 16993300 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 17054800 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 16993300 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 17054800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 7100 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 169782 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 16978200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 8000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 16993300 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 169782 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 7100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 7100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0004 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |